Advanced search
Publication Cover
Future Microbiology Volume 14, 2019 - Issue 2
Submit an article Journal homepage
203
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Temocillin: Is this the Right Momentum for its Global Use?

Indran Balakrishnan1 Department of Medical Microbiology,Royal Free London NHS Foundation Trust,London,UKView further author information
,
Vasiliki Koumaki2 Department of Microbiology,Medical School,University of Athens,Athens,GreeceView further author information
&
Athanasios Tsakris2 Department of Microbiology,Medical School,University of Athens,Athens,GreeceCorrespondence[email protected]
View further author information
Pages 81-83 | Received 15 Nov 2018, Accepted 03 Dec 2018, Published online: 15 Jan 2019

References

  • Livermore DM , TulkensPM . Temocillin revived . J. Antimicrob. Chemother.63 ( 2 ), 243 – 245 ( 2009 ).
  • Boon RJ , BealeAS . Studies with temocillin in a hamster model of antibiotic-associated colitis . Antimicrob. Agents Chemother.27 ( 6 ), 980 – 981 ( 1985 ).
  • Woodford N , PikeR , MeunierD , LoyR , HillR , HopkinsKL . In vitro activity of temocillin against multidrug-resistant clinical isolates of Escherichia coli, Klebsiella spp. and Enterobacter spp., and evaluation of high-level temocillin resistance as a diagnostic marker for OXA-48 carbapenemase . J. Antimicrob. Chemother.69 ( 2 ), 564 – 567 ( 2014 ).
  • Alexandre K , FantinB . Pharmacokinetics and pharmacodynamics of temocillin . Clin. Pharmacokinet.57 ( 3 ), 287 – 296 ( 2018 ).
  • The electronic Medicines Compendium Negaban 1g, powder for solution for injection/infusion . Summary of product characteristics (SmPC) ( 2018 ). www.medicines.org.uk/emc/product/466/smpc .
  • Fuchs PC , BarryAL , ThornsberryC , JonesRN . Interpretive criteria for temocillin disk diffusion susceptibility testing . Eur. J. Clin. Microbiol.4 ( 1 ), 30 – 33 ( 1985 ).
  • Alexandre K , ChauF , GuerinFet al. Activity of temocillin in a lethal murine model of infection of intra-abdominal origin due to KPC-producing Escherichia coli . J. Antimicrob. Chemother.71 ( 7 ), 1899 – 1904 ( 2016 ).
  • Laterre PF , WitteboleX , Van De VeldeSet al. Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration . J. Antimicrob. Chemother.70 ( 3 ), 891 – 898 ( 2015 ).
  • Livermore DM , HopeR , FaganEJ , WarnerM , WoodfordN , PotzN . Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from south-east England . J. Antimicrob. Chemother.57 ( 5 ), 1012 – 1014 ( 2006 ).
  • Glupczynski Y , HuangTD , BerhinCet al. In vitro activity of temocillin against prevalent extended-spectrum beta-lactamases producing Enterobacteriaceae from Belgian intensive care units . Eur. J. Clin. Microbiol. Infect. Dis.26 ( 11 ), 777 – 783 ( 2007 ).
  • Balakrishnan I , Awad-El-KariemFM , AaliAet al. Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC beta-lactamase-producing Enterobacteriaceae . J. Antimicrob. Chemother.66 ( 11 ), 2628 – 2631 ( 2011 ).
  • Galani I , KaraiskosI , KarantaniIet al. Epidemiology and resistance phenotypes of carbapenemase-producing Klebsiella pneumoniae in Greece, 2014 to 2016 . Euro. Surveill.23 ( 31 ), pii=1700775 ( 2018 ).
  • Koumaki V , PolitiL , GennimataV , PournarasS , BalakrishnanI , TsakrisA . Temocillin activity against KPC-producing Enterobacteriaceae in Greece . Presented at : 24th ECCMID . Vienna, Austria , 22–15 April 2017 .
  • Shields RK , ChenL , ChengSet al. Emergence of ceftazidime–avibactam resistance due to plasmid-borne blakpc-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections . Antimicrob. Agents Chemother.61 ( 3 ), e02097 – 16 ( 2017 ).
  • Rodriguez M , NelsonM , KellyJE , ElwardA , MorleySC . Successful use of temocillin as salvage therapy for cervical osteomyelitis secondary to multidrug-resistant Burkholderia cepacia . J. Pediatric Infect. Dis. Soc.3 ( 1 ), 77 – 80 ( 2014 ).
  • Van Dalem A , HerpolM , EchahidiFet al. In vitro susceptibility of Burkholderia cepacia complex isolated from cystic fibrosis patients to ceftazidime–avibactam and ceftolozane–tazobactam . Antimicrob. Agents Chemother.62 ( 9 ), e00590 – 18 ( 2018 ).
  • Lekkas A , GyiKM , HodsonME . Temocillin in the treatment of Burkholderia cepacia infection in cystic fibrosis . J. Cyst. Fibros.5 ( 2 ), 121 – 124 ( 2006 ).
  • Goire N , LahraMM , ChenMet al. Molecular approaches to enhance surveillance of gonococcal antimicrobial resistance . Nat. Rev. Microbiol.12 ( 3 ), 223 – 229 ( 2014 ).
  • Ghathian K , CalumH , GyssensIC , Frimodt-MollerN . Temocillin in vitro activity against recent clinical isolates of Neisseria gonorrhoeae compared with penicillin, ceftriaxone and ciprofloxacin . J. Antimicrob. Chemother.71 ( 4 ), 1122 – 1123 ( 2016 ).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.